Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Up 2,205.1% in March

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 225,900 shares, a growth of 2,205.1% from the February 28th total of 9,800 shares. Approximately 14.2% of the shares of the company are short sold. Based on an average daily trading volume, of 1,470,000 shares, the days-to-cover ratio is presently 0.2 days.

Sonoma Pharmaceuticals Stock Performance

Shares of SNOA opened at $2.88 on Friday. Sonoma Pharmaceuticals has a 1 year low of $1.90 and a 1 year high of $9.37. The firm has a fifty day moving average of $2.73 and a 200-day moving average of $2.85. The company has a market cap of $4.65 million, a price-to-earnings ratio of -0.72 and a beta of 1.56.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Wednesday, February 5th. The company reported ($0.59) EPS for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 68.98% and a negative net margin of 26.82%. Analysts predict that Sonoma Pharmaceuticals will post -0.67 EPS for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.